Teva’s recently appointed SVP of APAC and MENA Vivek Bachhawat details his relatively seamless journey from Actavis to Teva and the synergies inherent in both organizations even prior to the merger. He also highlights the company’s continued commitment to Singapore and its key regional role which will grow in importance as Teva taps into the country’s unique knowledge base and innovative capacities to intersect the prospects of technology and healthcare.
Having come out the other side of what might be considered two of the largest acquisitions in pharma history, how has your experience been transitioning from one organization to the next?
"Singapore will continue acting as a centralized hub for all activities in the APAC region, effectively driving the whole spectrum of capabilities such as supply chain, commercial excellence, and R&D."
